Reports

340B Impact on the Federal Budget

October 8, 2024

DSH Hospitals’ 340B Profit Often Exceeds Charity Care Spending

March 27, 2024

Charity Care at 340B Hospitals is on a Downward Trend

October 1, 2023

340B – A missed opportunity to address those that are medically underserved

July 4, 2023

What’s in a Name? Rural Referral Centers Capture 340B Discounts Without Serving Rural, Vulnerable Patients

July 1, 2023

Fulfilling a Social Responsibility: Comparing 340B and Non-340B Hospitals’ Contributions to Their Communities

October 24, 2022

340B Hospitals Continue to Provide Below Average Rates of Charity Care

February 1, 2022

340B – A missed opportunity to address those that are medically underserved

November 18, 2021

Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?

June 3, 2021

340B Drug Pricing Program: Analysis Reveals $40 Billion in Profits in 2019

May 1, 2021

The Impact of Growth in 340B Contract Pharmacy Arrangements – Six Years Later

October 1, 2020

Measuring the Relative Size of the 340B Program: 2018 Update

June 1, 2020

Public Opinion Poll on 340B Drug Pricing Program

March 1, 2020

Charity Care Provision by US Nonprofit Hospitals

February 17, 2020

GAO Report: Oversight of the Intersection with the Medicaid Drug Rebate Program Needs Improvement

January 1, 2020

GAO Report: Increased Oversight Needed to Ensure Nongovernmental Hospitals Meet Eligibility Requirements

January 1, 2020

Left Behind: An Analysis of Charity Care Provided by Hospitals Enrolled in the 340B Discount Program

November 1, 2019

GAO Report: Characteristics of Hospitals Participating and Not Participating in the 340B Program

July 18, 2018

Measuring the Relative Size of the 340B Program: 2017 Update

July 1, 2018

GAO Report: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement

June 28, 2018

340B Hospitals Continue to Expand: Growth and Distribution of Physician-Administered Drug Reimbursement Across Ten Therapeutic Areas

May 1, 2018

New Analysis Provides Evidence of Hospitals not Using the 340B Program as Intended

October 1, 2017

GAO Report: Update on Agency Efforts to Improve 340B Program Oversight

July 18, 2017

Measuring the Relative Size of the 340B Program: 2012–2017

July 1, 2017

COA: The 340B Drug Discount Program in Review: A Look at the Data and Evidence to Date

April 1, 2017

340B Program Sales Forecast: 2016-2021

December 1, 2016

Benefiting Hospitals, Not Patients: An Analysis of Charity Care Provided by Hospitals Enrolled in the 340B Discount Program

May 1, 2016

Compliance Trends with Hospital Charity Care Requirements

April 25, 2016

Fact Sheet on Distribution of Physician Administered Drugs in 340B

February 2, 2016

Hospital Acquisitions of Physician Practices and the 340B Program

June 8, 2015

GAO Report: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals

June 1, 2015

GAO Report Summary

February 2, 2015

Primer: Understanding the 340B Drug Pricing Program

June 4, 2014

Impact on Medicare Payments of Shift in Site of Care for Chemotherapy Administration

June 1, 2014

Innovations in Cancer Care and Implications for Health Systems

May 1, 2014

340B Covered Entity Acquisitions of Physician-based Oncology Practices

April 22, 2014

Unfulfilled Expectations: An Analysis of Charity Care Provided in 340B Hospitals

April 4, 2014

Unprecedented Growth, Questionable Policy: The 340B Drug Program

January 1, 2014

The Impact of Growth in 340B Contract Pharmacy Arrangements

January 1, 2014

Results of Analyses for Chemotherapy Administration Utilization and Chemotherapy Drug Utilization, 2005-2011 for Medicare Fee for-Service Beneficiaries

May 29, 2013

GAO Report: Manufacturer Discounts in the 340B Program Offer Benefits, But Federal Oversight Needs Improvement

September 1, 2011